Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Raymond James Trust N.A.

Raymond James Trust N.A. grew its position in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 3.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,246 shares of the medical instruments supplier’s stock after purchasing an additional 379 shares during the period. Raymond James Trust N.A.’s holdings in Becton, Dickinson and were worth $3,019,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Schroder Investment Management Group increased its position in shares of Becton, Dickinson and by 13.7% during the fourth quarter. Schroder Investment Management Group now owns 96,188 shares of the medical instruments supplier’s stock worth $24,189,000 after acquiring an additional 11,600 shares during the period. Clearstead Advisors LLC increased its position in shares of Becton, Dickinson and by 16.4% during the fourth quarter. Clearstead Advisors LLC now owns 2,125 shares of the medical instruments supplier’s stock worth $535,000 after acquiring an additional 299 shares during the period. Nuveen Asset Management LLC increased its position in shares of Becton, Dickinson and by 5.4% during the fourth quarter. Nuveen Asset Management LLC now owns 715,288 shares of the medical instruments supplier’s stock worth $179,879,000 after acquiring an additional 36,835 shares during the period. ETF Managers Group LLC purchased a new stake in shares of Becton, Dickinson and during the fourth quarter worth $4,950,000. Finally, Banco de Sabadell S.A increased its position in shares of Becton, Dickinson and by 17.1% during the fourth quarter. Banco de Sabadell S.A now owns 6,942 shares of the medical instruments supplier’s stock worth $1,751,000 after acquiring an additional 1,015 shares during the period. 86.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and

In related news, EVP Samrat S. Khichi sold 9,185 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total value of $2,392,141.40. Following the completion of the sale, the executive vice president now owns 5,928 shares in the company, valued at $1,543,888.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, EVP Samrat S. Khichi sold 9,185 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The shares were sold at an average price of $260.44, for a total value of $2,392,141.40. Following the completion of the sale, the executive vice president now owns 5,928 shares in the company, valued at $1,543,888.32. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP David Hickey sold 475 shares of the firm’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $265.00, for a total transaction of $125,875.00. Following the completion of the sale, the executive vice president now owns 3,331 shares of the company’s stock, valued at approximately $882,715. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,160 shares of company stock worth $5,036,751. Company insiders own 0.50% of the company’s stock.

Becton, Dickinson and Stock Performance

Shares of BDX stock opened at $237.19 on Friday. The stock’s 50-day moving average is $252.37 and its two-hundred day moving average is $253.93. The firm has a market cap of $67.65 billion, a price-to-earnings ratio of 40.89, a PEG ratio of 3.12 and a beta of 0.57. Becton, Dickinson and Company has a 1 year low of $231.46 and a 1 year high of $280.62. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.90 and a current ratio of 1.35.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its earnings results on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The business had revenue of $4.64 billion during the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter in the prior year, the firm earned $2.74 earnings per share. The business’s quarterly revenue was down 5.1% compared to the same quarter last year. Analysts predict that Becton, Dickinson and Company will post 11.31 earnings per share for the current year.

Becton, Dickinson and Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be paid a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 annualized dividend and a dividend yield of 1.47%. Becton, Dickinson and’s dividend payout ratio (DPR) is 60.00%.

Analysts Set New Price Targets

Several research firms recently commented on BDX. The Goldman Sachs Group increased their target price on Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. Stifel Nicolaus dropped their target price on Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. StockNews.com raised Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Saturday, September 10th. Citigroup lowered Becton, Dickinson and from a “neutral” rating to a “sell” rating and dropped their target price for the company from $265.00 to $235.00 in a report on Monday, July 11th. Finally, Wells Fargo & Company raised Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price on the stock in a report on Friday, June 24th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $277.63.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.